Navigation Links
ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
Date:6/24/2011

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.  If approved by the European Commission, Buccolam would be the first product approved through the centralized PUMA procedure.

Buccolam is oral midazolam provided in a pre-measured, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum line) delivery. Buccal midazolam has been shown in four clinical studies to be either comparable or superior in both its effectiveness and speed of onset of action to the current standard treatment, rectally-administered diazepam, for terminating pediatric convulsive epileptic seizures.

"The potential approval of Buccolam would address a major challenge for physicians currently prescribing rectally-administered diazepam for acute seizures, namely that it can be difficult to use and may be socially unacceptable in the community," said Professor Ian Wong, Director of the Centre for Paediatric Pharmacy Research at the School of Pharmacy, University of London. "Midazolam is recommended for treating prolonged acute convulsive seizures according to published treatment guidelines in European countries, and the availability of Buccolam – an oromucosal formulation of midazolam – would be an important, convenient and welcomed alternative to treat seizures in pediatric and adolescent patients."

The CHMP is responsible for issuing the EMA's scientific evaluation and opinions on all Marketing Au
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
2. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
3. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
4. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
5. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
6. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
7. ViroPharma to Participate In Three May Healthcare Investor Conferences
8. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
11. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 P&S ... "Global Industry Insight: Microfluidic Devices Market Development ... trends, DRO analysis, market segmentation, market size ... scenario and top competitor profiles. ... Microfluidic devices  market ...
(Date:7/29/2015)... 29, 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ... revenue interest assignment agreement (the "Agreement") in which it ... ARIA ) with up to $200 million in revenue ... revenues of Iclusig ® (ponatinib).  Funding of the ... of $50 million each, with the initial amount having ...
(Date:7/29/2015)... -- Cogentix Medical, Inc. (NASDAQ: CGNT ), a global ... financial results for the first quarter of fiscal year 2016, ... Monday, August 10, 2015. The Company will ... on Monday, August 10, 2015 at 4:30 p.m. Eastern Time ... Chief Executive Officer, and Brett Reynolds , Chief Financial ...
Breaking Medicine Technology:Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2
... TOPAZ Technologies, a leading provider of biomedical research ... ML Weekes & Company, a professional services firm ... strategic partnership.  As a result of this partnership, ... solution through ML Weekes & Company,s RAMS grantsERA ...
... Texas, Nov. 16, 2010 Argon Medical Devices, Inc. ... licensing agreement with Rex Medical, LP ("Rex Medical") for ... dialysis catheter ™ on a global basis. UltraStream ™ ... patients receiving dialysis treatments. Argon will be ...
Cached Medicine Technology:TOPAZ Technologies and ML Weekes & Company Announce Partnership 2TOPAZ Technologies and ML Weekes & Company Announce Partnership 3Argon Medical Devices Announces Exclusive License and Distribution Agreement for 'UltraStream™' Chronic Hemodialysis Catheter 2
(Date:7/29/2015)... ... July 29, 2015 , ... ... that Columbia University Medical Center, located in New York, NY, selected the ReadyCam ... easy for physicians and scientists to immediately access worldwide TV and cable news ...
(Date:7/29/2015)... ... July 29, 2015 , ... Abt Associates has named ... Health division. In her position, Ramkeesoon will help build and expand work ... Ramkeesoon spent close to a decade at ICF International, most recently as a ...
(Date:7/29/2015)... ... 29, 2015 , ... Andrzej Klos, M.D., has been reviewed and approved as ... 38 years, is motivated each and every day by his sincere desire to help ... his many awards and accolades, which include multiple listings in many highly regarded medical ...
(Date:7/29/2015)... ... 29, 2015 , ... Today the nonprofit Alliance for ... Vaccination in Older Adults, that provides a comprehensive overview of the factors that ... health care experts can improve patient compliance. , Although influenza, pneumococcal, tetanus, and ...
(Date:7/29/2015)... ... , ... " Core Organizer ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... help anyone get organized. , Wouldn’t it be great if everyone could be a ...
Breaking Medicine News(10 mins):Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Get More Organized with the Core Organizer App 2
... Health and the University of Colorado Denver have discovered a ... acute lung injury. Acute lung injury (ALI) is often caused ... in the blood, and fluid in the lungs. It is ... afflicting almost 200,000 people in the United States each year, ...
... Pharos Innovations, a pioneer in,assisting clients to ... a device-free remote monitoring platform,today announced it is ... of two key appointments in medical informatics and ... http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGO ) , ...
... N.Y., Jan. 16 Bausch & Lomb, the ... Valenti, III, will join Bausch & Lomb as ... month."Pete possesses deep leadership experience, as well as ... Stuart Heap, corporate vice president and global president, ...
... 16 /PRNewswire-FirstCall/ - Thomas E. Gardner, Chairman, announced ... appointed to the NUCRYST Pharmaceuticals, Board of Directors. ... Executive Officer of The Westaim Corporation ("Westaim"), NUCRYST,s ... common shares. Prior to his appointment as President ...
... 16 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced updates on ... and international markets in,2009. , ... of ten products, achieving the goals,for new product ...
... in Guangdong ProvincePROVO, Utah, Jan. 15 Nu Skin ... that it has received official notification from the Chinese ... selling activities in four cities in the Guangdong province ... Skin Enterprises the opportunity to offer a direct selling ...
Cached Medicine News:Health News:Gene associated with reduced mortality from acute lung injury 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 3Health News:Bausch & Lomb Names Peter Valenti, III, as President, North America, Vision Care 2Health News:NUCRYST Pharmaceuticals appoints a new director 2Health News:NUCRYST Pharmaceuticals appoints a new director 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 2Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 4Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 5Health News:Nu Skin Enterprises Receives Broader Direct Selling Authorization in China 2
... relieve low back discomfort. Strong mesh elastic ... comfortable, custom fit. Optional metal stays may ... spine. Wide elastic adjustment panels provide varying ... easily accessed and adjusted. Simple hood and ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
... Pelvic Brace is the solution to the ... off-the-shelf brace fits like a custom and ... minutes. The Bledsoe Simple Pelvic Brace limits ... and adduction in 15 increments from -30 ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: